Price
No data yet.
Social Signal Score
Analyst Ratings
16 analystsRevenue
$89.00M+407.71%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Elizabeth Barrett
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 300
- Beta
- 1.64
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -1.90
Financials
Revenue
$89.00M+407.7%Net Income
$-1.46M-111.9%EBITDA
$4.47M-68.0%Free Cash Flow
$-15.27M-215.4%EPS (diluted)
$-0.03-102.5%Shares Outstanding (diluted)
50.56M+361.3%Operating Expenses
$73.17MCash & Debt
$90.55MReturn of Capital
$0.00Revenue by Segment (annual)
$93.99MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $109.79M | $-153.49M | $-3.19 |
| 2024 | $90.40M | $-126.87M | $-2.96 |
| 2023 | $82.71M | $-102.24M | $-3.55 |
| 2022 | $64.36M | $-109.78M | $-4.79 |
| 2021 | $48.04M | $-110.82M | $-4.96 |
| 2020 | $11.80M | $-128.48M | $-5.90 |
| 2019 | $18.0K | $-105.15M | $-4.90 |
| 2018 | $1.13M | $-75.66M | $-4.80 |
| 2017 | $8.16M | $-20.00M | $-2.06 |
| 2016 | $17.53M | $-1.94M | $-0.16 |
| 2015 | $0.00 | $-12.69M | $-5.51 |
| 2014 | $0.00 | $-4.56M | $-1.98 |
| 2013 | $0.00 | $-3.31M | $-1.56 |
Valuation
URGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (14)
- Newszacks.com·3d ago·Neutral
Implied Volatility Surging for Urogen Pharma Stock Options Investors need to pay close attention to URGN stock based on the movements in the options market lately.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
UroGen: Opportunity Builds As Rough Patch Gets Brutal UroGen Pharma is rated a 'Buy' at a depressed ~$1.21B market cap, with potential for ~65% upside in 2027. Management has established a promising setup, featuring two approved products—Jelmyto and Zusdori—leveraging the proprietary RT Gel delivery system. Jelmyto's sales have stalled below initial expectations, while Zusdori is positioned for significant growth and could drive future upside.
View source ↗ - Newsmarketbeat.com·18d ago·Positive
Urogen Pharma Q3 Earnings Call Highlights Urogen Pharma NASDAQ: URGN reported third-quarter revenue of $89 million, more than triple the $27.5 million recorded a year earlier, as sales of bladder cancer treatment ZUSDURI continued to grow. The company said it expects to achieve profitability and generate positive cash flow in the fourth quarter of 2026.
View source ↗ - Newsfool.com·18d ago·Neutral
The Gel That Became a Business Zosturi quarterly net product revenue reached $68 million. Repeat prescribers expanded to 50% of total Zosturi writers.
View source ↗ - Newszacks.com·18d ago·Neutral
Urogen Pharma (URGN) Reports Q3 Loss, Beats Revenue Estimates Urogen Pharma (URGN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of $0.05. This compares to a loss of $0.69 per share a year ago.
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights ZUSDURI ® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growth The FDA accepted UroGen's NDA for UGN-103 (next-generation novel mitomycin-based formulation) for review; PDUFA goal date set for June 14, 2027 Announced first patient dosed in the UGN-501 Phase 1 trial Conference call and webcast to be held today at 10:00 AM ET PRIN
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026 Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET
View source ↗ - Newsseekingalpha.com·40d ago·Positive
UroGen Pharma: An Emerging GARP Stock UroGen Pharma has pulled back 30% after a 208% rally, driven by Zusduri's strong launch as the only approved non-surgical LG-IR-NMIBC therapy. Zusduri's rapid uptake, favorable patient preference, and robust clinical data support continued growth, with patent protection until 2044 and 95% reimbursement coverage. URGN faces looming clinical competition but currently only contends with TURBT, positioning it for robust growth through at least 2027.
View source ↗ - Newszacks.com·53d ago·Neutral
Here's Why You Should Add URGN Stock to Your Portfolio Now UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.
View source ↗ - Newszacks.com·93d ago·Neutral
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet The consensus price target hints at a 27.1% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newsprnewswire.com·94d ago·Positive
…ctables, today announced an equity investment agreement and a strategic Option and Research License Agreement (the Option Agreement) with UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers.
View source ↗ - Newsglobenewswire.com·94d ago·Neutral
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head and neck cancer PRINCETON, N.J., Au
View source ↗ - Newsglobenewswire.com·97d ago·Neutral
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC PRINCETON, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
View source ↗ - Newszacks.com·100d ago·Neutral
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗
Earnings
Mon, Mar 1(in 3 months)
Consensus estimate $0.41 per share
Typical surprise -5.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.03 vs $0.11miss
- Wed, Aug 5$-0.28 vs $-0.27miss
- Wed, May 6$-0.47 vs $-0.56beat
- Mon, Mar 2$-0.54 vs $-0.52miss
- Thu, Nov 6$-0.69 vs $-0.72beat
- Thu, Aug 7$-1.05 vs $-0.82miss
Estimates and results for URGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by URGN officers and directors.
- Bought
- —
- Sold
- $5.4m
0 trades
25 trades
- Degnan Chrissold
- Schoenberg Marksold
- Smith Jason Drewsold
- Schoenberg Marksold
- Schoenberg Marksold
- Schoenberg Marksold
- Schoenberg Marksold
- Schoenberg Marksold
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in URGN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
